Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...

Cardiogenic shock (CS) is a life-threatening condition leading to poor prognosis and high morbidity. The related inadequate cardiac output carries to tissue hypoperfusion, hypoxia and multi-organ ...

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...

Cardiogenic shock is the most common cause of death for patients hospitalized with acute myocardial infarction. The Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock ...

CS may present as an early complication following ST elevation and MI. In the SHOCK trial, the median time from MI to shock onset was 5.0 hours (25th to 75th percentile, 2.2-12.0 hours ...

Most of the change in stage of cardiogenic shock (CS) occurred within the first 24 hours of presentation ... Mortality and use of temporary mechanical circulatory support was similar in stage E for ...

Baylor Scott & White The Heart Hospital-Plano in Texas cut times of cardiogenic shock diagnosis in half after implementing a quality improvement project that included nurse education and an ...

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

The company has collaborated with ACTION to gather real-world data supporting the on-label use of heart pumps.

Hospitals with lower risk-adjusted in-hospital mortality rates (RAMR) among patients with cardiogenic shock following acute myocardial infarction (AMI) demonstrated higher rates of revascularization ...